<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04842110</url>
  </required_header>
  <id_info>
    <org_study_id>D0000000151</org_study_id>
    <nct_id>NCT04842110</nct_id>
  </id_info>
  <brief_title>Eon™ FR 1064 Full Abdomen Clinical Study Protocol</brief_title>
  <official_title>A Prospective, Controlled, Standardized, Multi-center, Single-treatment, Single- Arm Evaluation of the EonTM FR 1064 nm Device to Reduce Abdominal Fat</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dominion Aesthetic Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dominion Aesthetic Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a marketing study intended to provide additional data for marketing purposes for the&#xD;
      eon™ FR is FDA 510(k) which has been cleared for non-invasive lipolysis of the abdomen to&#xD;
      achieve disruption of adipocyte cells intended for non-invasive aesthetic use to achieve a&#xD;
      desired aesthetic effect. This device is intended for individuals with a Body Mass Index&#xD;
      (BMI) of 30 kg/m2 or less.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 24, 2019</start_date>
  <completion_date type="Actual">December 21, 2019</completion_date>
  <primary_completion_date type="Actual">December 21, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Photographic Evaluations as a Measure of Effectiveness</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Photographs of the treatment area will be obtained at baseline and 12 weeks post treatment and be evaluated by blinded independent readers to correctly identify pre-treatment (baseline) photographs compared to 12 weeks post treatment photographs in order to determine effectiveness of device.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Adipose Layer Thickness</measure>
    <time_frame>12 weeks</time_frame>
    <description>Ultrasound measurements of adipose layer thickness will be collected at baseline and 12 weeks after procedure to evaluate changes between both.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Satisfaction</measure>
    <time_frame>12 weeks</time_frame>
    <description>Subject Questionnaires will be completed by subjects at the end of study to determine the subject satisfaction with procedure.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Abdominal Obesity</condition>
  <arm_group>
    <arm_group_label>1064 Full Abdomen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>eonTM FR 1064 nm device Patient will be treated with the eonTM FR 1064 nm device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Experimental: eonTM FR 1064 nm device</intervention_name>
    <description>The subject treatment area - abdomen, was treated with the 1064 nm wavelength laser.</description>
    <arm_group_label>1064 Full Abdomen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is a healthy male or female &gt; 18 years or older seeking treatment for unwanted&#xD;
             fat in the abdomen.&#xD;
&#xD;
          -  Subject must be able to read, understand and sign the Informed Consent Form (ICF) in&#xD;
             English.&#xD;
&#xD;
          -  Subject has sufficient thickness (≥ 25 mm) of adipose tissue on the abdomen area.&#xD;
&#xD;
          -  Study subjects must agree to maintain their current diet and weight (not gaining or&#xD;
             losing greater than ±5 lbs.&#xD;
&#xD;
          -  Subject must be willing and able to adhere to the treatment and follow-up visit&#xD;
             schedule.&#xD;
&#xD;
          -  Subject must be willing to have limited sun exposure for the duration of the study,&#xD;
             including the follow-up period.&#xD;
&#xD;
          -  Subject is willing to have photographs and ultrasound measurements taken of the&#xD;
             treated area, which will be de-identified in evaluations and may be used in&#xD;
             presentations and/or publications.&#xD;
&#xD;
          -  Female subjects must be using medically acceptable form of birth control during the&#xD;
             entire course of the study or may be post-menopausal, surgically sterilized.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Aesthetic fat reduction procedure in the treatment area within the previous year.&#xD;
&#xD;
          -  Pregnant in the last 3 months, intending to become pregnant, postpartum or nursing in&#xD;
             last 6 months&#xD;
&#xD;
          -  Unstable weight within the last 6 months (+ or - 3% weight change in the prior six&#xD;
             months)&#xD;
&#xD;
          -  Subject has an infection, dermatitis or a rash in the treatment area.&#xD;
&#xD;
          -  Subject has tattoos or jewelry in the treatment area or within the treatment area site&#xD;
             or photography frame.&#xD;
&#xD;
          -  Subject has a history of keloid scarring, hypertrophic scarring or of abnormal wound&#xD;
             healing.&#xD;
&#xD;
          -  Subject has a history of immunosuppression/immune deficiency disorders or currently&#xD;
             using immunosuppressive medications.&#xD;
&#xD;
          -  Subject has a history of a known bleeding disorder.&#xD;
&#xD;
          -  Subject has a known photosensitivity to the study laser wavelength, history of&#xD;
             ingesting medications known to induce photosensitivity, or history of seizure&#xD;
             disorders due to light.&#xD;
&#xD;
          -  Subject has known collagen, vascular disease or scleroderma.&#xD;
&#xD;
          -  Subject has undergone a surgery or procedure in the treatment area within 6 months of&#xD;
             treatment, which is still healing.&#xD;
&#xD;
          -  Subject suffers from significant concurrent illness, such as insulin-dependent&#xD;
             diabetes, peripheral vascular disease or peripheral neuropathy.&#xD;
&#xD;
          -  Subject is undergoing systemic chemotherapy for the treatment of cancer.&#xD;
&#xD;
          -  Subject is using gold therapy for disorders such as rheumatologic disease or lupus.&#xD;
&#xD;
          -  Subject has participated in a study of another device or drug within three months&#xD;
             prior to enrollment or during the study.&#xD;
&#xD;
          -  As per the investigator's discretion, the subject has any physical or mental condition&#xD;
             which might make it unsafe for the subject to participate in this study.&#xD;
&#xD;
          -  Subject has ongoing use of steroids or secondary rheumatoid drugs.&#xD;
&#xD;
          -  Subject is actively taking psychotropic medications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fiala Aesthetics</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 8, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity, Abdominal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

